Q3 2024 Eris Lifesciences Ltd Earnings Call Transcript
Key Points
- Eris Lifesciences Ltd (BOM:540596) achieved a significant market rank improvement from #29 in 2017 to #21 in 2023.
- The company has generated an operating cash flow of around INR 2,100 crores over the past six years.
- Eris Lifesciences Ltd (BOM:540596) has successfully diversified into new therapies such as dermatology, CNS, women's health, nephrology, and insulins.
- The company's EBITDA margin has consistently been more than 35%, with an operating cash flow to EBITDA ratio of more than 75%.
- Eris Lifesciences Ltd (BOM:540596) has projected strong cash generation, expecting operating cash flow in excess of INR 1,800 crores over the next three financial years.
- The acquisition of Swiss Parenterals involves a significant financial commitment, with INR 200 crores funded through debt financing and INR 437.5 crores in non-convertible debentures.
- There is a disparity between the standalone and consolidated performance, with standalone performance showing a meaningful drop.
- The company faces challenges in integrating and scaling the newly acquired Swiss Parenterals business, particularly in the Indian market.
- The dermatology acquisitions have experienced some disruptions, particularly in transitioning stockists and stabilizing sales.
- The company's net debt at the end of the quarter stood at INR 887 crores, indicating a substantial debt load.
Ladies and gentlemen, good day, and welcome to the Q3 FY '24 Earnings Conference Call of Eris Lifesciences Limited. We have with us on the call today Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Chief Operating Officer and Executive Director. (Operator Instructions) Please note that this call is being recorded.
I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir. Please go ahead.
Am I audible now?
Yes, sir. Please go ahead.
Wonderful. Welcome, everybody, to our quarter 3 conference call. As we get into today's conversation -- yes. So as we start today's conversation, we will start with recapping our journey since the public listing due date. So we had
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
